Ngenla
Ngenla ingredients
| Active ingredient | Strength |
|---|---|
| Somatrogon | 24 mg/1.2mL, 60 mg/1.2mL |
What Ngenla is used for
The FDA lists the approved uses on the official label (below). In the EU, somatrogon is approved as Ngenla for:
Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ngenla
- Generic name
- Somatrogon-ghla
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Recombinant Human Growth Hormone
- FDA approval
- Biologic licence (BLA) BLA761184
- On the US market since
- 2023
Official information
- Ngenla prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Somatrogon-ghla)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ngenla?
Ngenla (Somatrogon-ghla) is a specialist medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Ngenla?
Ngenla contains Somatrogon (24 mg/1.2mL, 60 mg/1.2mL).
Is Ngenla approved in Europe?
The same active substance is approved in the EU as Ngenla.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA